Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Jefferies 2011 Global Healthcare Conference in New York. The presentation is scheduled for June 9 at 11:00 a.m. EDT (8:00 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter and ViroPharma to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin and Cinryze®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact  
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
3. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
4. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
8. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics to Host Research Day for Investors and Analysts
11. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research ... disciplines for more than half a century. Despite their essential roles in human ... widely known that molecular tags developed for this purpose also tag other, more abundant, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... shopping cart. Now mobile responsive, the new website makes it easy to navigate ... in between. Users can now find detailed product information, educational industry content and ...
(Date:8/11/2017)... 2017  Market researcher Kalorama Information was ... regarding the telemedicine market.  The telemedicine market ...  The article, "Heart and Asthma Monitors? ... information from Kalorama Information,s Remote Patient Monitoring ...  (Sleep, Diabetes, Vital Signs /EKG and ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):